Biofrontera establishes subsidiary in the US
(Thomson Reuters ONE) -
Biofrontera AG /
Biofrontera establishes subsidiary in the US
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Preparing for scheduled market entry in 2016
* Monica Tamborini appointed CEO of Biofrontera's US operations
Leverkusen, 20 April 2015 - Biofrontera AG (AIM/FSE: B8F), the biopharmaceutical
company focusing on skin cancer, has formed a wholly-owned US subsidiary,
Biofrontera Inc., registered in Wilmington, Delaware. This company is intended
to lay the ground for marketing and sales activities upon the expected FDA
approval for the products Ameluz® and BF-RhodoLED® in 2016.
Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica
has over 20 years' experience managing US companies in the healthcare sector.
After earning master's degrees in economics and business administration with
summa cum laude from Boston University und Suffolk University, and receiving the
"Delta Alpha PI Society Award", Monica worked in various sectors before joining
the pharmaceutical industry. Since then, Monica has held various positions as
CFO and COO. In addition to her expertise in finance Monica has, as Managing
Director of Calix Consulting, in recent years concentrated on the communication
with the Food and Drug Administration (FDA) and the development of quality
management systems, which are mandatory for pharmaceutical and medical device
businesses.
Commenting, CEO of Biofrontera, Prof. Dr. Hermann Lübbert, said: "We are very
happy that we will be able to rely on Monica's broad expertise when establishing
the infrastructure for the distribution of our products in the US.
"An efficient infrastructure, supported by a perfectly well-attuned quality
management system, is the foundation of every pharmaceutical company's success.
Monica Tamborini's professional background makes her the perfect choice for the
development and management of our US business. Since we are expecting FDA
approval for our products by the summer of 2016, it is extremely important to
start preparing now for the distribution of our products. Monica will initially
conduct further market analyses on which the decision will be based whether the
cooperation with another distribution partner will be required."
Ends
Enquiries, please contact:
Biofrontera AG +49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer press(at)biofrontera.com
Thomas Schaffer, Chief Financial Officer www.biofrontera.com
IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514
Jürgen Benker
Nomad and Broker: Shore Capital +44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs
IR UK: Seton Services +44(0) 20 7603 6797
Toni Vallen
Financial PR: Gable Communications +44(0) 20 7193 7463
John Bick +44 (0)7872 061007
Background:
The Biofrontera Group (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical
company specialising in the development, sale and distribution of drugs and
medical cosmetics for the care and treatment of skin diseases. Biofrontera's
most important product is Ameluz(®), a prescription drug which is approved in
Europe for the treatment of mild and moderate actinic keratosis (superficial
skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first
German pharmaceutical start-up company to obtain centralised approval for a drug
it has developed itself. The company also plans for Ameluz(®) to be approved for
basal cell carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United States.
The company also markets the Belixos(®) dermatological range of cosmetics.
Belixos(®) products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the moment,
Belixos(®) cream, gel and scalp tonic are available through Amazon.
The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.
www.biofrontera.com
This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These forward-
looking statements reflect the opinion of Biofrontera at the time of this
communication and involve certain known and unknown risks. The actual results
achieved by Biofrontera may differ significantly from future results or
performances which are published in its forward-looking statements. Biofrontera
assumes no responsibility to update its forward-looking statements.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Biofrontera AG via GlobeNewswire
[HUG#1912330]
Unternehmensinformation / Kurzprofil:
Datum: 20.04.2015 - 08:00 Uhr
Sprache: Deutsch
News-ID 386797
Anzahl Zeichen: 6142
contact information:
Town:
Leverkusen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 138 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biofrontera establishes subsidiary in the US"
steht unter der journalistisch-redaktionellen Verantwortung von
Biofrontera AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
